The promoter was used to drive neuron-specific expression of human MAPT with three point mutations that result in the following amino acid changes: G272V, P301L and R406W. These mutations have been identified in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). (J:73872)